Longeveron Inc.
For the period ended Oct 26, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 26, 2026 · Filed Oct 26, 2026
Use the contents to explore the available documents and sections.
LGVN$1.81+5.8%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Presentation
Presentation
| Date: | Sunday, November 8, 2026 |
|---|---|
| Time: | 10:10am CDT |
| Session: | Featured Science, FS.07, Heart Failure Care for Novel Phenotypes |
| Title: | ELPIS II: A Phase 2b Randomized Clinical Trial to Evaluate the Efficacy and Safety of Laromestrocel as Adjunct |
| Therapy During Stage II Palliation for Hypoplastic Left Heart Syndrome | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.